Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Global Hyperimmune Globulins key players include CSL Behring, Grifols, etc. Global top two manufacturers hold a share over 50%.
Asia-Pacific is the largest market, with a share about 30%, followed by Europe and North America, both have a share over 50 percent.
In terms of product, Rho(D) Immunoglobulins is the largest segment, with a share about 33%. And in terms of application, the largest application is Government Institution, followed by Private Sector, etc.
The global Hyperimmune Globulins market was valued at US$ 1527.4 million in 2020 and is expected to reach US$ 2540.7 million by the end of 2029, growing at a CAGR of 7.0% during 2021-2029.
This report focuses on Hyperimmune Globulins volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Hyperimmune Globulins market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Hyperimmune Globulins Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2029. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Hepatitis B Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Rho(D) Immunoglobulins
Other
Segment by Application
Government Institutions
Private Sector
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics
1 Hyperimmune Globulins Market Overview
1.1 Product Overview and Scope of Hyperimmune Globulins
1.2 Hyperimmune Globulins Segment by Type
1.2.1 Global Hyperimmune Globulins Sales Growth Rate Comparison by Type (2021-2029)
1.2.2 Hepatitis B Immunoglobulins
1.2.3 Rabies Immunoglobulins
1.2.4 Tetanus Immunoglobulins
1.2.5 Rho(D) Immunoglobulins
1.2.6 Other
1.3 Hyperimmune Globulins Segment by Application
1.3.1 Global Hyperimmune Globulins Sales Comparison by Application: (2021-2029)
1.3.2 Government Institutions
1.3.3 Private Sector
1.3.4 Other
1.4 Global Hyperimmune Globulins Market Size Estimates and Forecasts
1.4.1 Global Hyperimmune Globulins Revenue 2016-2029
1.4.2 Global Hyperimmune Globulins Sales 2016-2029
1.4.3 Hyperimmune Globulins Market Size by Region: 2016 Versus 2021 Versus 2029
2 Hyperimmune Globulins Market Competition by Manufacturers
2.1 Global Hyperimmune Globulins Sales Market Share by Manufacturers (2016-2021)
2.2 Global Hyperimmune Globulins Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Hyperimmune Globulins Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Hyperimmune Globulins Manufacturing Sites, Area Served, Product Type
2.5 Hyperimmune Globulins Market Competitive Situation and Trends
2.5.1 Hyperimmune Globulins Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Hyperimmune Globulins Players Market Share by Revenue
2.5.3 Global Hyperimmune Globulins Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Hyperimmune Globulins Retrospective Market Scenario by Region
3.1 Global Hyperimmune Globulins Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Hyperimmune Globulins Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Hyperimmune Globulins Market Facts & Figures by Country
3.3.1 North America Hyperimmune Globulins Sales by Country
3.3.2 North America Hyperimmune Globulins Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Hyperimmune Globulins Market Facts & Figures by Country
3.4.1 Europe Hyperimmune Globulins Sales by Country
3.4.2 Europe Hyperimmune Globulins Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Hyperimmune Globulins Market Facts & Figures by Region
3.5.1 Asia Pacific Hyperimmune Globulins Sales by Region
3.5.2 Asia Pacific Hyperimmune Globulins Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Hyperimmune Globulins Market Facts & Figures by Country
3.6.1 Latin America Hyperimmune Globulins Sales by Country
3.6.2 Latin America Hyperimmune Globulins Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Hyperimmune Globulins Market Facts & Figures by Country
3.7.1 Middle East and Africa Hyperimmune Globulins Sales by Country
3.7.2 Middle East and Africa Hyperimmune Globulins Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Hyperimmune Globulins Historic Market Analysis by Type
4.1 Global Hyperimmune Globulins Sales Market Share by Type (2016-2021)
4.2 Global Hyperimmune Globulins Revenue Market Share by Type (2016-2021)
4.3 Global Hyperimmune Globulins Price by Type (2016-2021)
5 Global Hyperimmune Globulins Historic Market Analysis by Application
5.1 Global Hyperimmune Globulins Sales Market Share by Application (2016-2021)
5.2 Global Hyperimmune Globulins Revenue Market Share by Application (2016-2021)
5.3 Global Hyperimmune Globulins Price by Application (2016-2021)
6 Key Companies Profiled
6.1 CSL Behring
6.1.1 CSL Behring Corporation Information
6.1.2 CSL Behring Description and Business Overview
6.1.3 CSL Behring Hyperimmune Globulins Sales, Revenue and Gross Margin (2016-2021)
6.1.4 CSL Behring Hyperimmune Globulins Product Portfolio
6.1.5 CSL Behring Recent Developments/Updates
6.2 Grifols
6.2.1 Grifols Corporation Information
6.2.2 Grifols Description and Business Overview
6.2.3 Grifols Hyperimmune Globulins Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Grifols Hyperimmune Globulins Product Portfolio
6.2.5 Grifols Recent Developments/Updates
6.3 Biotest
6.3.1 Biotest Corporation Information
6.3.2 Biotest Description and Business Overview
6.3.3 Biotest Hyperimmune Globulins Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Biotest Hyperimmune Globulins Product Portfolio
6.3.5 Biotest Recent Developments/Updates
6.4 Kedrion
6.4.1 Kedrion Corporation Information
6.4.2 Kedrion Description and Business Overview
6.4.3 Kedrion Hyperimmune Globulins Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Kedrion Hyperimmune Globulins Product Portfolio
6.4.5 Kedrion Recent Developments/Updates
6.5 CBPO
6.5.1 CBPO Corporation Information
6.5.2 CBPO Description and Business Overview
6.5.3 CBPO Hyperimmune Globulins Sales, Revenue and Gross Margin (2016-2021)
6.5.4 CBPO Hyperimmune Globulins Product Portfolio
6.5.5 CBPO Recent Developments/Updates
6.6 Emergent (Cangene)
6.6.1 Emergent (Cangene) Corporation Information
6.6.2 Emergent (Cangene) Description and Business Overview
6.6.3 Emergent (Cangene) Hyperimmune Globulins Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Emergent (Cangene) Hyperimmune Globulins Product Portfolio
6.6.5 Emergent (Cangene) Recent Developments/Updates
6.7 Kamada
6.6.1 Kamada Corporation Information
6.6.2 Kamada Description and Business Overview
6.6.3 Kamada Hyperimmune Globulins Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Kamada Hyperimmune Globulins Product Portfolio
6.7.5 Kamada Recent Developments/Updates
6.8 CNBG
6.8.1 CNBG Corporation Information
6.8.2 CNBG Description and Business Overview
6.8.3 CNBG Hyperimmune Globulins Sales, Revenue and Gross Margin (2016-2021)
6.8.4 CNBG Hyperimmune Globulins Product Portfolio
6.8.5 CNBG Recent Developments/Updates
6.9 Hualan Bio
6.9.1 Hualan Bio Corporation Information
6.9.2 Hualan Bio Description and Business Overview
6.9.3 Hualan Bio Hyperimmune Globulins Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Hualan Bio Hyperimmune Globulins Product Portfolio
6.9.5 Hualan Bio Recent Developments/Updates
6.10 Shanghai RAAS
6.10.1 Shanghai RAAS Corporation Information
6.10.2 Shanghai RAAS Description and Business Overview
6.10.3 Shanghai RAAS Hyperimmune Globulins Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Shanghai RAAS Hyperimmune Globulins Product Portfolio
6.10.5 Shanghai RAAS Recent Developments/Updates
6.11 Sichuan Yuanda Shuyang
6.11.1 Sichuan Yuanda Shuyang Corporation Information
6.11.2 Sichuan Yuanda Shuyang Hyperimmune Globulins Description and Business Overview
6.11.3 Sichuan Yuanda Shuyang Hyperimmune Globulins Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Sichuan Yuanda Shuyang Hyperimmune Globulins Product Portfolio
6.11.5 Sichuan Yuanda Shuyang Recent Developments/Updates
6.12 ADMA Biologics
6.12.1 ADMA Biologics Corporation Information
6.12.2 ADMA Biologics Hyperimmune Globulins Description and Business Overview
6.12.3 ADMA Biologics Hyperimmune Globulins Sales, Revenue and Gross Margin (2016-2021)
6.12.4 ADMA Biologics Hyperimmune Globulins Product Portfolio
6.12.5 ADMA Biologics Recent Developments/Updates
7 Hyperimmune Globulins Manufacturing Cost Analysis
7.1 Hyperimmune Globulins Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Hyperimmune Globulins
7.4 Hyperimmune Globulins Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Hyperimmune Globulins Distributors List
8.3 Hyperimmune Globulins Customers
9 Hyperimmune Globulins Market Dynamics
9.1 Hyperimmune Globulins Industry Trends
9.2 Hyperimmune Globulins Growth Drivers
9.3 Hyperimmune Globulins Market Challenges
9.4 Hyperimmune Globulins Market Restraints
10 Global Market Forecast
10.1 Hyperimmune Globulins Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Hyperimmune Globulins by Type (2022-2029)
10.1.2 Global Forecasted Revenue of Hyperimmune Globulins by Type (2022-2029)
10.2 Hyperimmune Globulins Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Hyperimmune Globulins by Application (2022-2029)
10.2.2 Global Forecasted Revenue of Hyperimmune Globulins by Application (2022-2029)
10.3 Hyperimmune Globulins Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Hyperimmune Globulins by Region (2022-2029)
10.3.2 Global Forecasted Revenue of Hyperimmune Globulins by Region (2022-2029)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Hyperimmune Globulins Sales (K Units) Growth Rate Comparison by Type (2021-2029)
Table 2. Global Hyperimmune Globulins Sales (K Units) Comparison by Application (2021-2029)
Table 3. Global Hyperimmune Globulins Market Size by Region (US$ Million) (2016 VS 2021 VS 2029)
Table 4. Key Manufacturers Hyperimmune Globulins Covered in This Study
Table 5. Global Hyperimmune Globulins Sales (K Units) of Key Manufacturers (2016-2021)
Table 6. Global Hyperimmune Globulins Sales Market Share by Manufacturers (2016-2021)
Table 7. Global Hyperimmune Globulins Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Hyperimmune Globulins Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Hyperimmune Globulins Average Price (USD/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Hyperimmune Globulins Manufacturing Sites and Area Served
Table 11. Manufacturers Hyperimmune Globulins Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Hyperimmune Globulins by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hyperimmune Globulins as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Hyperimmune Globulins Sales by Region (2016-2021) & (K Units)
Table 16. Global Hyperimmune Globulins Sales Market Share by Region (2016-2021)
Table 17. Global Hyperimmune Globulins Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Hyperimmune Globulins Sales by Country (2016-2021) & (K Units)
Table 19. North America Hyperimmune Globulins Sales Market Share by Country (2016-2021)
Table 20. North America Hyperimmune Globulins Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Hyperimmune Globulins Revenue Market Share by Country (2016-2021)
Table 22. Europe Hyperimmune Globulins Sales by Country (2016-2021) & (K Units)
Table 23. Europe Hyperimmune Globulins Sales Market Share by Country (2016-2021)
Table 24. Europe Hyperimmune Globulins Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Hyperimmune Globulins Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Hyperimmune Globulins Sales by Region (2016-2021) & (K Units)
Table 27. Asia Pacific Hyperimmune Globulins Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Hyperimmune Globulins Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Hyperimmune Globulins Revenue Market Share by Region (2016-2021)
Table 30. Latin America Hyperimmune Globulins Sales by Country (2016-2021) & (K Units)
Table 31. Latin America Hyperimmune Globulins Sales Market Share by Country (2016-2021)
Table 32. Latin America Hyperimmune Globulins Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Hyperimmune Globulins Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Hyperimmune Globulins Sales by Country (2016-2021) & (K Units)
Table 35. Middle East and Africa Hyperimmune Globulins Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Hyperimmune Globulins Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Hyperimmune Globulins Revenue Market Share by Country (2016-2021)
Table 38. Global Hyperimmune Globulins Sales (K Units) by Type (2016-2021)
Table 39. Global Hyperimmune Globulins Sales Market Share by Type (2016-2021)
Table 40. Global Hyperimmune Globulins Revenue (Million US$) by Type (2016-2021)
Table 41. Global Hyperimmune Globulins Revenue Share by Type (2016-2021)
Table 42. Global Hyperimmune Globulins Price (USD/Unit) by Type (2016-2021)
Table 43. Global Hyperimmune Globulins Sales (K Units) by Application (2016-2021)
Table 44. Global Hyperimmune Globulins Sales Market Share by Application (2016-2021)
Table 45. Global Hyperimmune Globulins Revenue (Million US$) by Application (2016-2021)
Table 46. Global Hyperimmune Globulins Revenue Share by Application (2016-2021)
Table 47. Global Hyperimmune Globulins Price (USD/Unit) by Application (2016-2021)
Table 48. CSL Behring Corporation Information
Table 49. CSL Behring Description and Business Overview
Table 50. CSL Behring Hyperimmune Globulins Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 51. CSL Behring Hyperimmune Globulins Product
Table 52. CSL Behring Recent Developments/Updates
Table 53. Grifols Corporation Information
Table 54. Grifols Description and Business Overview
Table 55. Grifols Hyperimmune Globulins Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 56. Grifols Hyperimmune Globulins Product
Table 57. Grifols Recent Developments/Updates
Table 58. Biotest Corporation Information
Table 59. Biotest Description and Business Overview
Table 60. Biotest Hyperimmune Globulins Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 61. Biotest Hyperimmune Globulins Product
Table 62. Biotest Recent Developments/Updates
Table 63. Kedrion Corporation Information
Table 64. Kedrion Description and Business Overview
Table 65. Kedrion Hyperimmune Globulins Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 66. Kedrion Hyperimmune Globulins Product
Table 67. Kedrion Recent Developments/Updates
Table 68. CBPO Corporation Information
Table 69. CBPO Description and Business Overview
Table 70. CBPO Hyperimmune Globulins Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 71. CBPO Hyperimmune Globulins Product
Table 72. CBPO Recent Developments/Updates
Table 73. Emergent (Cangene) Corporation Information
Table 74. Emergent (Cangene) Description and Business Overview
Table 75. Emergent (Cangene) Hyperimmune Globulins Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 76. Emergent (Cangene) Hyperimmune Globulins Product
Table 77. Emergent (Cangene) Recent Developments/Updates
Table 78. Kamada Corporation Information
Table 79. Kamada Description and Business Overview
Table 80. Kamada Hyperimmune Globulins Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 81. Kamada Hyperimmune Globulins Product
Table 82. Kamada Recent Developments/Updates
Table 83. CNBG Corporation Information
Table 84. CNBG Description and Business Overview
Table 85. CNBG Hyperimmune Globulins Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 86. CNBG Hyperimmune Globulins Product
Table 87. CNBG Recent Developments/Updates
Table 88. Hualan Bio Corporation Information
Table 89. Hualan Bio Description and Business Overview
Table 90. Hualan Bio Hyperimmune Globulins Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 91. Hualan Bio Hyperimmune Globulins Product
Table 92. Hualan Bio Recent Developments/Updates
Table 93. Shanghai RAAS Corporation Information
Table 94. Shanghai RAAS Description and Business Overview
Table 95. Shanghai RAAS Hyperimmune Globulins Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 96. Shanghai RAAS Hyperimmune Globulins Product
Table 97. Shanghai RAAS Recent Developments/Updates
Table 98. Sichuan Yuanda Shuyang Corporation Information
Table 99. Sichuan Yuanda Shuyang Description and Business Overview
Table 100. Sichuan Yuanda Shuyang Hyperimmune Globulins Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 101. Sichuan Yuanda Shuyang Hyperimmune Globulins Product
Table 102. Sichuan Yuanda Shuyang Recent Developments/Updates
Table 103. ADMA Biologics Corporation Information
Table 104. ADMA Biologics Description and Business Overview
Table 105. ADMA Biologics Hyperimmune Globulins Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 106. ADMA Biologics Hyperimmune Globulins Product
Table 107. ADMA Biologics Recent Developments/Updates
Table 108. Production Base and Market Concentration Rate of Raw Material
Table 109. Key Suppliers of Raw Materials
Table 110. Hyperimmune Globulins Distributors List
Table 111. Hyperimmune Globulins Customers List
Table 112. Hyperimmune Globulins Market Trends
Table 113. Hyperimmune Globulins Growth Drivers
Table 114. Hyperimmune Globulins Market Challenges
Table 115. Hyperimmune Globulins Market Restraints
Table 116. Global Hyperimmune Globulins Sales Forecast by Type (2022-2029) & (K Units)
Table 117. Global Hyperimmune Globulins Sales Market Share Forecast by Type (2022-2029)
Table 118. Global Hyperimmune Globulins Revenue Forecast by Type (2022-2029) & (US$ Million)
Table 119. Global Hyperimmune Globulins Revenue Market Share Forecast by Type (2022-2029)
Table 120. Global Hyperimmune Globulins Sales Forecast by Application (2022-2029) & (K Units)
Table 121. Global Hyperimmune Globulins Sales Market Share Forecast by Application (2022-2029)
Table 122. Global Hyperimmune Globulins Revenue Forecast by Application (2022-2029) & (US$ Million)
Table 123. Global Hyperimmune Globulins Revenue Market Share Forecast by Application (2022-2029)
Table 124. Global Hyperimmune Globulins Sales Forecast by Region (2022-2029) & (K Units)
Table 125. Global Hyperimmune Globulins Sales Market Share Forecast by Region (2022-2029)
Table 126. Global Hyperimmune Globulins Revenue Forecast by Region (2022-2029) & (US$ Million)
Table 127. Global Hyperimmune Globulins Revenue Market Share Forecast by Region (2022-2029)
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Hyperimmune Globulins
Figure 2. Global Hyperimmune Globulins Market Share by Type in 2020 & 2029
Figure 3. Hepatitis B Immunoglobulins Product Picture
Figure 4. Rabies Immunoglobulins Product Picture
Figure 5. Tetanus Immunoglobulins Product Picture
Figure 6. Rho(D) Immunoglobulins Product Picture
Figure 7. Other Product Picture
Figure 8. Global Hyperimmune Globulins Market Share by Application in 2020 & 2029
Figure 9. Government Institutions
Figure 10. Private Sector
Figure 11. Other
Figure 12. Global Hyperimmune Globulins Revenue, (US$ Million), 2016 VS 2021 VS 2029
Figure 13. Global Hyperimmune Globulins Market Size 2016-2029 (US$ Million)
Figure 14. Global Hyperimmune Globulins Sales 2016-2029 (K Units)
Figure 15. Global Hyperimmune Globulins Market Size Market Share by Region: 2016 VS 20210 VS 2029
Figure 16. Hyperimmune Globulins Sales Share by Manufacturers in 2020
Figure 17. Global Hyperimmune Globulins Revenue Share by Manufacturers in 2020
Figure 18. The Global 5 and 10 Largest Hyperimmune Globulins Players: Market Share by Revenue in 2020
Figure 19. Hyperimmune Globulins Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 20. Global Hyperimmune Globulins Sales Market Share by Region (2016-2021)
Figure 21. Global Hyperimmune Globulins Sales Market Share by Region in 2020
Figure 22. Global Hyperimmune Globulins Revenue Market Share by Region (2016-2021)
Figure 23. Global Hyperimmune Globulins Revenue Market Share by Region in 2020
Figure 24. U.S. Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. Canada Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Germany Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. France Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. U.K. Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Italy Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Russia Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. China Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Japan Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. South Korea Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. India Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Australia Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Taiwan Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Indonesia Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Thailand Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Malaysia Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Philippines Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Vietnam Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Mexico Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Brazil Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Argentina Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Turkey Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Saudi Arabia Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. U.A.E Hyperimmune Globulins Revenue Growth Rate (2016-2021) (US$ Million)
Figure 48. Sales Market Share of Hyperimmune Globulins by Type (2016-2021)
Figure 49. Sales Market Share of Hyperimmune Globulins by Application (2016-2021)
Figure 50. Sales Market Share of Hyperimmune Globulins by Application in 2020
Figure 51. Revenue Share of Hyperimmune Globulins by Application (2016-2021)
Figure 52. Revenue Share of Hyperimmune Globulins by Application in 2020
Figure 53. Manufacturing Cost Structure of Hyperimmune Globulins
Figure 54. Manufacturing Process Analysis of Hyperimmune Globulins
Figure 55. Hyperimmune Globulins Industrial Chain Analysis
Figure 56. Channels of Distribution
Figure 57. Distributors Profiles
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
The research methodology employed by VICResearch has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of VICResearch. VICResearch’s methodology can be divided into five stages:
Stage 1: Secondary research
The research team first works with magazines, industry trade group, and administration that operate in the research field. The information provided by our in-house documentation service helps us carrying out further research. Our team which has the experience as well as the knowledge efficiently extracts the accurate information from existing source.
Stage 2: Primary research: interviews with trade sources
After the first stage, the research team conducts large number of face-to-face or telephone interviews with the representative companies operating in the research field. The analysts attempt to obtain a chance to talk with leading players in the field as well as with small companies. The upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers are all included in the interviews. The data gathered during the interview is then carefully checked and compared with the secondary research.
Stage 3: Analysis of the gathered data
The analysis team checks and synthesizes the data gathered during the first two stages. To validate the data, a second series of interviews can be conducted.
Stage 4: Quantitative data
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by VICResearch. The data is based on the estimates obtained during stage 3.
The research team also provides appreciation and analysis of the market and the quantitative data contained in the reports. The data is consequently unique to VICResearch.
Stage 5: Quality control
Before publishing, every report goes under a rigorous checking and editing process, which is done by experience management team to ensure the reliability of the published data. Each analyst in the research team receives support and on-going training which is part of the VICResearch’s internal quality process.
Consulting report: +86-15323335301 020-31521856
